Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

Role and mechanism of Integrin α5β1 in bone formation and disease

Li X., Hu G., Guo J., Chang B., Yi X., Yao T.

Narrative Review on Osteoarthritis, published in Front Cell Dev Biol (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Front Cell Dev Biol (2025)
Reported sample size
—
Source database
Europe PMC
PMID
40894924
PMCID
PMC12391163
DOI
10.3389/fcell.2025.1632710
Citations
2

Abstract (original English)

Integrin α5β1 is a key signaling protein between cells and the extracellular matrix. It plays crucial roles in biological processes such as cell adhesion, migration, and differentiation. Recent studies have shown that integrin α5β1 is significantly involved in bone formation and related diseases. Integrin α5β1 participates in the differentiation of mesenchymal stem cells into osteoblasts. It interacts with the CCN family and the bone morphogenetic protein pathway to upregulate the expression of osteogenic markers, promoting the formation of mineralization nodules. Additionally, it can mediate mechanical force stimulation to upregulate osteogenic gene expression and promote bone formation. In diseases such as osteoporosis, osteoarthritis, and bone metastasis, integrin α5β1 mediates abnormal cell-matrix adhesion and migration, promoting pathological bone resorption and inhibiting bone formation, thereby exacerbating bone loss. Therefore, integrin α5β1 may be a potential therapeutic target for these bone diseases. Elucidating its mechanism of action will help understand the homeostatic regulation of bone metabolism and provide ideas for the development of novel therapeutic strategies for skeletal diseases.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research